The first Russian direct antiviral drug for COVID-19 with proven clinical efficacy has been named Avifavir
Moscow, May 22, 2020 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group plan to start production of Avifavir, which has proved to be highly effective in treating patients with coronavirus in the first phase of its clinical trials. The necessary applications for production have been submitted to the Federal Service for Intellectual Property.
Avifavir, which disrupts the reproduction mechanisms of coronavirus, is the first Russian direct antiviral drug that has been shown to be effective in clinical trials. The drug has been well studied, since it has been used in Japan since 2014 against severe forms of influenza.
The launch of the final stage of clinical trials, which will involve 330 patients, was approved by the Ministry of Health of the Russian Federation 21 May 2020. The drug proved to be highly effective during the first stage of clinical trials involving I.M. Sechenov First Moscow State Medical University, Lomonosov Moscow State University and other centres.
- According to the results of the first stage, Avifavir demonstrated safety with no new or previously unreported side effects detected;
- Median elimination of the virus took four days compared to nine days with standard therapy, according to the study involving 60 patients;
- Efficacy of the drug is above 80%, a criterion for a drug with high antiviral activity;
- Following the first four days of treatment, 65% of the 40 patients who took Avifavir tested negative for coronavirus, which is twice as many as in the standard therapy group. By day 10, the number of patients whose tests returned negative results reached 90%;
- The body temperature of 68% of patients taking Avifavir returned to normal earlier (on the third day) than in the control group (on the sixth day);
- The drug is undergoing trials in Moscow, Saint-Petersburg, Tver, Nizhny Novgorod, Smolensk, Ryazan, Kazan, Ufa and in the Republic of Dagestan.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:
“Avifavir shows better results compared to other drugs that are currently being tested in Russia and abroad. RDIF and ChemRar are cooperating with both leading medical institutions and state regulatory bodies. We look forward to receiving approval for the production of Avifavir in the near future.”
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB1.8 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 15 countries that total more than $40 bn.
RDIF takes active steps to counteract COVID-19:
- RDIF and partners have launched the production of the unique Russian-Japanese EMG diagnostic system, which generates results in 30 minutes with an accuracy of more than 99.9% in both stationary and unmatched portable mini-laboratories. The Japan Bank for International Cooperation has joined the project through the Russia-Japan Investment Fund;
- RDIF and the ChemRar Group are preparing for the mass production of the Avifavir, a drug that has proven effective in the treatment of infected patients in clinical trials in Russia;
- RDIF has launched a project to diagnose and detect pneumonia, including that caused by coronavirus, using CT scans combined with the Russian-UAE artificial intelligence (AI) technology developed jointly by Group 42 (G42), RDIF and Medscan Group;
- RDIF has provided support to the public in observing the lockdown restrictions and self-isolation regime, driving a several-fold increase in telemedicine consultations via the Doctis service, as well as in access and subscriptions to the ivi online media library, delivery of Elementaree meal kits and demand for products and services of other RDIF portfolio companies;
- The Mother and Child Group, an RDIF's portfolio company, has repurposed its largest clinical hospital Lapino to treat patients with COVID-19 symptoms.
- RDIF was one of the initiators of the Alliance against coronavirus, which also includes the Russian Union of Industrialists and Entrepreneurs (RUIE), Yandex, Mail.ru Group and the Rossiya Segodnya international news agency. RDIF is actively involved in key initiatives and charity projects.
Further information can be found at www.rdif.ru
ChemRar Group unites R&D service and investment companies in the field of innovative pharmaceuticals for the development and commercialization of innovative medicines, diagnostics, preventive care and new treatments of life-threatening diseases in Russia and abroad. Further information can be found at http://en.chemrar.ru/
For additional information contact:
Russian Direct Investment Fund
Tel: +7 495 644 34 14, ext. 2395
Mobile: +7 916 110 31 41
Andrew Leach / Maria Shiryaevskaya
Tel: +44 (0) 20 7796 4133
Mobile +7 9262067871